The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $640,522 Project Grant to The Leland Stanford Junior University to conduct research aimed at identifying microbial-derived proteins that can modulate macrophage function and thereby enhance cancer immunotherapy efficacy. The 5-year project, commencing on May 1, 2025, will utilize high-throughput screening approaches to systematically examine thousands of microbial microproteins and determine their impact on...
The National Cancer Institute (NCI) awarded a $148,568.00 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University (Stanford University). The grant, titled "INTEGRATING HIGHLY MULTIPLEXED IMMUNOFLUORESCENCE WITH LABEL-FREE 2D HYPERSPECTRAL CHEMICAL IMAGING TO INTERROGATE THE COLORECTAL CANCER TUMOR-INVASIVE FRONT," supports research to develop an innovative technology platform that combines highly multiplexed immunofluorescence and...
This National Science Foundation (NSF) Project Grant, awarded under the Biological Sciences program (CFDA 47.074), provides $750,000 to Stanford University to develop new technologies for studying RNA, the essential molecules that carry genetic information and play crucial roles in cell functions. The key products and services to be delivered under this 3-year award include: Creating non-destructive methods to directly study RNA localization and interactions within living cells, achieving...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $135,594 to The Leland Stanford Junior University to develop novel pharmacological approaches to rewire oncogenic gene expression and induce apoptosis in cancer cells. The project aims to (1) discover chemical inducers of proximity that can kill aggressive leukemias driven by mixed-lineage leukemia gene fusions, and (2) elucidate the structural and biophysical...
The National Cancer Institute (NCI) awarded a $509,448 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The Leland Stanford Junior University. The grant supports research to identify the antigen-presenting cell (APC) population responsible for inducing tumor-specific regulatory T cells that promote metastatic progression, and to develop immunotherapeutic strategies to reprogram APCs and overcome tumor immune tolerance. The research aims to delineate the key...
The National Cancer Institute (NCI) awarded a $355,706 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Washington University in St. Louis to conduct research on understanding the role of the long non-coding RNA, RAMS11, in promoting non-small cell lung cancer (NSCLC). The research aims to determine how RAMS11 interacts with the NRF2 transcription factor to regulate cancer-specific gene expression programs, with the goal of identifying new biomarkers and targeted therapeutic...
The National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), awarded a $487,973 Project Grant to The Leland Stanford Junior University on January 1, 2025. This grant supports scientific research aimed at investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in the pathogenesis of acute myeloid leukemia (AML). The research will explore key questions related to the clonal evolution, kinetics, and cell non-autonomous effects of pHSCs,...
This Project Grant award, totaling $170,655.00, was made by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to The Leland Stanford Junior University (Stanford University) on July 1, 2025. The award supports the development of a new molecular method for mapping protein trafficking between glioblastoma (GBM) cells and other brain cell types, such as neurons, astrocytes, microglia, and endothelial cells, in an in vivo setting. The project aims to create an...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel therapeutic strategy targeting mutant p53, a gene known to drive tumor progression, metastasis, and therapy resistance in more than half of human cancers. The $590,625 award to the University of California, Davis (UC Davis) will fund a 5-year project (3/1/2025 - 2/28/2030) to investigate how the CDK4/6-RBM38-eIF4G axis regulates mutant p53 expression,...
The National Cancer Institute (NCI) awarded a $377,102 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Johns Hopkins University to investigate the effects of MYC oncogene overexpression on protein translation dynamics and ribosome collision-induced cellular stress in cancer. The 2.5-year project aims to define how increased protein synthesis demands driven by MYC upregulation impact translational activity, ribosome collisions, and susceptibility to...
The National Cancer Institute (NCI) awarded a 3-year, $337,509 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University. The grant, awarded on September 1, 2024, supports high-throughput measurements to identify functional effector domains within human RNA-binding proteins (RBPs) and determine how dysregulation of RBP function leads to cancer. The research aims to systematically characterize how RBPs and their effector domains regulate gene expression post-transcriptionally, and how oncogenic mutations in these domains may disrupt normal RBP activity and contribute to cancer development. Specifically, the grant will fund the use of a high-throughput recruitment assay to screen thousands of RBP protein segments and identify those with regulatory effects on RNA levels and translation. The findings will provide new insights into the modular architecture of RBPs and how specific effector domains mediate their impact on RNA fate and gene expression, with implications for understanding and targeting the molecular drivers of oncogenesis.